
    
      Part 1: Approximately 32 subjects will be enrolled into 4 cohorts to receive PN-232 or
      placebo as single doses.

      Part 2: Up to 40 subjects will be enrolled into 4 cohorts to receive PN-232 or placebo once
      daily for 10 days.

      Part 3: Twelve subjects will receive single doses of PN-232 in a 3-way, randomized, crossover
      fashion.

      In total, approximately 84 subjects will participate.
    
  